Maridebart Cafraglutide
- Generic Name
- Maridebart Cafraglutide
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 120
- Registration Number
- NCT06976372
- Locations
- πΊπΈ
CenExel, Anaheim, California, United States
πΊπΈCenExel Collaborative Neuroscience Research, LLC Los Alamitos, Los Alamitos, California, United States
πΊπΈFortrea Clinical Research Unit - Dallas, Dallas, Texas, United States
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3501
- Registration Number
- NCT06858839
- Locations
- πΊπΈ
Indago Research and Health Center, Hialeah, Florida, United States
πΊπΈYale School of Medicine, New Haven, Connecticut, United States
πΊπΈPinnacle Research Group LLC, Anniston, Alabama, United States
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 999
- Registration Number
- NCT06858878
- Locations
- πΊπΈ
Alliance for Multispecialty Research Mobile, Mobile, Alabama, United States
πΊπΈGilbert Center for Family Medicine, Gilbert, Arizona, United States
πΊπΈDesert Clinical Research, Mesa, Arizona, United States
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 409
- Registration Number
- NCT06660173
- Locations
- π΅π±
Centrum Badan Klinicznych Piotr Napora lekarze spolka partnerska, Wroclaw, Poland
π΅π±Futuremeds spolka z ograniczona odpowiedzialnoscia, Wroclaw, Poland
π΅π·Latin Clinical Trial Center, San Juan, Puerto Rico
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 20
- Registration Number
- NCT06352892
- Locations
- ππ°
Queen Mary Hospital, Hong Kong, Hong Kong
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes MellitusOverweightObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 592
- Registration Number
- NCT05669599
- Locations
- πΊπΈ
Progressive Medical Research, Port Orange, Florida, United States
πΊπΈDiablo Clinical Research, Walnut Creek, California, United States
πΊπΈResearch Innovations LLC dba Internal Medicine Care Inc, Beavercreek, Ohio, United States
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT05056246
- Locations
- πΊπΈ
WCCT Global LLC, Cypress, California, United States
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 110
- Registration Number
- NCT04478708
- Locations
- πΊπΈ
Anaheim Clinical Trials, Anaheim, California, United States
πΊπΈOrange County Research Center, Tustin, California, United States
πΊπΈClinical Pharmacology of Miami, LLC, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.